AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease

RecruitingNAAges 40 Years - anyAllAnhui Medical University
💬

In plain words

What the trial is, and whether it could suit you

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 40 years old; 2. Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))\[1\]; 3. Have no history of drug adjustment within 4 weeks before treatment and the entire study period; 4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4; 5. MMSE ≥22,able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy. Exclusion Criteria: 1. Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above); 2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.); 3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment; 4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc. 5. The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures; 6. Diagnosed with a neuropsychiatric disorder other than PD 7. Have a history of drug abuse or drug use; 8. Participants in any clinical trial within the previous 6 month; 9. Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months; 10. Other conditions deemed unsuitable for inclusion by the investigator.
💊

What it tests

  • transcranial magnetic stimulation
📍

Where

1 site
Cognitive Neuropsychology Lab Anhui Medical University
Hefei, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy